Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974659 | 0.79 | HSD17B10 (0.41) | TDP1ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL28124379 | 0.79 | POLB (0.43) | POLBTDP1ALDH1A1CYP2A6TSHR | |
| SCHEMBL10392260 | 0.78 | TSHR (0.48) | TDP1ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL10624612 | 0.78 | CYP2A6 (0.48) | TDP1ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL7913536 | 0.78 | ALDH1A1 (0.39) | POLBTDP1ALDH1A1CYP2A6TSHR | |
| SCHEMBL30274454 | 0.76 | POLB (0.52) | POLBTDP1ALDH1A1CYP2A6TSHR | |
| SCHEMBL596646 | 0.76 | POLB (0.57) | POLBTDP1ALDH1A1CYP2A6TSHR | |
| SCHEMBL4698955 | 0.76 | POLB (0.52) | POLBTDP1ALDH1A1CYP2A6TSHR | |
| SCHEMBL182660 | 0.76 | CYP1A2 (0.52) | TDP1ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL30559660 | 0.76 | CYP1A2 (0.52) | TDP1ALDH1A1KDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037307-B2 | — | — | 2024-07-16 | — | — | US | disclosed |
| US-12037307-B2 | — | — | 2024-07-16 | — | — | US | disclosed |
| US-20230227400-A1 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | API CORPORATION (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20230227400-A1 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | API CORPORATION (JP) | 2023-07-20 | — | — | US | disclosed |
| US-11643386-B2 | High purity 2-naphthylacetonitrile and method for producing same | API CORPORATION (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11643386-B2 | High purity 2-naphthylacetonitrile and method for producing same | API CORPORATION (JP) | 2023-05-09 | — | — | US | disclosed |
| EP-3950664-A1 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | API Corporation (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220009880-A1 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | API CORPORATION (JP) | 2022-01-13 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-0393941-A1 | Naphthalene derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4897405-A | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| US-4745115-A | ANTIALLERGENS, RHEUMATIC DISEASES | BEECHAM GROUP P.L.C. (GB) | 1988-05-17 | — | — | US | disclosed |
| EP-0183369-A2 | Dihydroisoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1986-06-04 | — | — | EP | disclosed |
| US-4217306-A | ANTIARRHYTHMIA AGENTS | G. D. SEARLE & CO. (US) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643386-B2 | High purity 2-naphthylacetonitrile and method for producing same | SULT2A1, GNPAT, SULT1A1 | POLB 515/4885TDP1 3726/4885ALDH1A1 49/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | POLB 2769/4885TDP1 1542/4885ALDH1A1 412/4885 |
| US-20220009880-A1 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | SULT2A1, GNPAT, SULT1A1 | POLB 515/4885TDP1 3726/4885ALDH1A1 49/4885 |
| US-12037307-B2 | — | SULT2A1, SULT1A1, GNPAT | POLB 665/4885TDP1 3551/4885ALDH1A1 40/4885 |
| US-20230227400-A1 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | NAT1, CYP2J2, NQO1 | POLB 651/4885TDP1 3467/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.